Compare Merck & Co., Inc. (MRK) vs Permian Resources Corporation Class A Common Stock (PR) Price & Performance

Merck & Co., Inc.Trade

Permian Resources Corporation Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Permian Resources Corporation Class A Common Stock — how do they compare? Merck & Co., Inc. trades at $142.16 (market cap $352.29B), while Permian Resources Corporation Class A Common Stock trades at $22.64 (market cap $18.57B). The key difference: Merck & Co., Inc. is far larger — about 19× Permian Resources Corporation Class A Common Stock's market cap, and Permian Resources Corporation Class A Common Stock pays the higher dividend (2.84%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Permian Resources Corporation Class A Common Stock for 0 Days on average.

	MRK	PR
Market Cap	$352.29B	$18.57B
Volume	6,348,796	7,560,985
Sector	Health	Energy
52-Week High	$156.43	$24.49
52-Week Low	$82.49	$12.09
Typical Hold Time	98 Days	0 Days
Enterprise Value	$399.05B	$21.57B
Dividend Yield	2.38%	2.84%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.

The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.

Permian Resources Corporation Class A Common Stock

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRK

18% Buy82% Sell

Avg holding period · 98 Days

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

MRK

Global DPP-4 inhibitors market to grow to $15.5B by 2032, driven by type 2 diabetes demand and generics expansion.PRNewsWire · 17 hours agoNeutral HP, Merck, and Seagate paid dividends on Oct 7, with Merck leading in per-share payout and HP offering the highest yield.24/7 Wall Street · 23 hours agoBullish Dutch court blocks Merck's Keytruda SC sales in Europe for patent infringement.PRNewsWire · 1 day agoNeutral View details →

View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Permian Resources Corporation Class A Common Stock

Permian Resources explores for and produces oil and natural gas in the Permian Basin. Its operations are concentrated in the Delaware Basin of West Texas and New Mexico.